Business Description
![Amgen Inc Amgen Inc logo](https://static.gurufocus.com/logos/0C00000AB1.png?14)
Amgen Inc
NAICS : 325412
SIC : 2834
ISIN : US0311621009
Share Class Description:
AMGN: Ordinary SharesCompare
Compare
Traded in other countries / regions
AMGN.USAAMG N.MexicoAMGN34.BrazilAMGN.ArgentinaAMG.GermanyAMGN.AustriaAMGd.UKAMGN.Chile04332.Hong Kong IPO Date
1983-06-17Description
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.15 | |||||
Equity-to-Asset | 0.07 | |||||
Debt-to-Equity | 10.57 | |||||
Debt-to-EBITDA | 5.3 | |||||
Interest Coverage | 1.93 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 1.49 | |||||
Beneish M-Score | -2.26 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.7 | |||||
3-Year EBITDA Growth Rate | 7.7 | |||||
3-Year EPS without NRI Growth Rate | 14.9 | |||||
3-Year FCF Growth Rate | -6.6 | |||||
3-Year Book Growth Rate | -10.6 | |||||
Future 3-5Y EPS without NRI Growth Rate | 4.66 | |||||
Future 3-5Y Total Revenue Growth Rate | 6.73 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 58.34 | |||||
9-Day RSI | 54.29 | |||||
14-Day RSI | 53.47 | |||||
6-1 Month Momentum % | 15.24 | |||||
12-1 Month Momentum % | 29.48 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.26 | |||||
Quick Ratio | 0.89 | |||||
Cash Ratio | 0.43 | |||||
Days Inventory | 233.01 | |||||
Days Sales Outstanding | 77.76 | |||||
Days Payable | 51.79 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 2.7 | |||||
Dividend Payout Ratio | 0.52 | |||||
3-Year Dividend Growth Rate | 10 | |||||
Forward Dividend Yield % | 2.74 | |||||
5-Year Yield-on-Cost % | 4.32 | |||||
3-Year Average Share Buyback Ratio | 2.5 | |||||
Shareholder Yield % | -4.51 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 63.3 | |||||
Operating Margin % | 20.02 | |||||
Net Margin % | 10.12 | |||||
FCF Margin % | 17.72 | |||||
ROE % | 49.5 | |||||
ROA % | 3.39 | |||||
ROIC % | 9.25 | |||||
ROC (Joel Greenblatt) % | 95.2 | |||||
ROCE % | 9.15 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 56.59 | |||||
Forward PE Ratio | 16.86 | |||||
PE Ratio without NRI | 19.5 | |||||
Shiller PE Ratio | 27.77 | |||||
Price-to-Owner-Earnings | 42.01 | |||||
PEG Ratio | 3.55 | |||||
PS Ratio | 5.72 | |||||
PB Ratio | 29.8 | |||||
Price-to-Free-Cash-Flow | 32.34 | |||||
Price-to-Operating-Cash-Flow | 27.49 | |||||
EV-to-EBIT | 34.14 | |||||
EV-to-Forward-EBIT | 15.8 | |||||
EV-to-EBITDA | 19.47 | |||||
EV-to-Forward-EBITDA | 12.28 | |||||
EV-to-Revenue | 7.44 | |||||
EV-to-Forward-Revenue | 6.93 | |||||
EV-to-FCF | 41.97 | |||||
Price-to-Projected-FCF | 1.77 | |||||
Price-to-DCF (Earnings Based) | 1.12 | |||||
Price-to-DCF (FCF Based) | 2.47 | |||||
Price-to-Median-PS-Value | 1.03 | |||||
Earnings Yield (Greenblatt) % | 2.93 | |||||
FCF Yield % | 3.1 | |||||
Forward Rate of Return (Yacktman) % | 9.28 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AMGN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Amgen Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 30,934 | ||
EPS (TTM) ($) | 5.81 | ||
Beta | 0.6 | ||
Volatility % | 24.63 | ||
14-Day RSI | 53.47 | ||
14-Day ATR ($) | 6.946271 | ||
20-Day SMA ($) | 326.682 | ||
12-1 Month Momentum % | 29.48 | ||
52-Week Range ($) | 248.38 - 346.85 | ||
Shares Outstanding (Mil) | 537.33 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Amgen Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Amgen Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Amgen Inc Frequently Asked Questions
What is Amgen Inc(AMGN)'s stock price today?
The current price of AMGN is $328.80. The 52 week high of AMGN is $346.85 and 52 week low is $248.38.
When is next earnings date of Amgen Inc(AMGN)?
The next earnings date of Amgen Inc(AMGN) is 2024-10-31 Est..
Does Amgen Inc(AMGN) pay dividends? If so, how much?
The Dividend Yield %  of Amgen Inc(AMGN) is 2.7% (As of Today), Highest Dividend Payout Ratio of Amgen Inc(AMGN) was 1.71. The lowest was 0.35. And the median was 0.45. The  Forward Dividend Yield % of Amgen Inc(AMGN) is 2.74%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |